Princess Margaret Lung Group to receive award for exceptional Phase III and IND Program Teams
April 30, 2014

 The Princess Margaret Cancer Centre lung group, under the direction of Dr. Geoffrey Liu, has won the inaugural award of recognition to exceptional Phase III and Investigational New Drug (IND) Program Teams to acknowledge their effort and dedication to the success of clinical trials from the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). 
 
Results from a double-blind placebo-controlled trial in patients with incurable Stage III and IV non-small cell lung cancer after failure of standard therapy for advanced metastatic disease was reviewed by the IND Executive for IND Trial Team Awards and by the Clinical Trials Committee (CTC) for Phase III Trial Team Awards. The team was selected as one of two to receive the prestigious inaugural awards of recognition. Team leader, Dr. Geoffrey Liu, is the Alan B. Brown Chair in Molecular Genomics.
 
"I am very proud of the team at Princess Margaret Cancer Centre," said Elizabeth Eisenhauer MD FRCPC, Interim Director, NCIC Clinical Trials Group. "You make a big difference to cancer patients through your NCIC CTG participation and we are pleased to be able to recognize this through this award."
 
The award of recognition will be presented at the Plenary Session of the Spring Meeting of the NCIC CTG on May 2, 2014. 
 
You have an old version of Adobe's Flash Player. Get the latest Flash player.